Rheumatoid Arthritis | Unmet Need | US/EU | 2016
Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral Jak inhibitor Xeljanz (Pfizer). Given rheumatologists’ long-standing familiarity with the safety and efficacy profiles of the TNF-alpha inhibitors and non-TNF-alpha biologics Orencia (Bristol-Myers Squibb), Rituxan/MabThera (Biogen/Roche), and RoActemra/Actemra (Roche), new agents face formidable challenges in gaining uptake in this crowded market. Nonetheless, all marketed RA drugs are associated with substantial nonresponder rates, highlighting a significant unmet need and commercial opportunity for novel therapies that can offer improved efficacy and safety.
Related Market Assessment Reports
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
Report
Systemic Lupus Erythematosus – Access & Reimbursement – Access & Reimbursement – Systemic Lupus Erythematosus (US)
The U.S. systemic lupus erythematosus (SLE) therapy market is largely genericized and off-label. With the exception of GSK’s Benlysta, the firstagents approved for the indication in almost 60…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
